Combination treatment with progesterone and vitamin D hormone is more effective than monotherapy in ischemic stroke: The role of BDNF/TrkB/Erk1/2 signaling in neuroprotection

Abstract

We investigated whether combinatorial post-injury treatment with progesterone (P4) and vitamin D hormone (VDH) would reduce ischemic injury more effectively than P4 alone in an oxygen glucose deprivation (OGD) model in primary cortical neurons and in a transient middle cerebral artery occlusion (tMCAO) model in rats. In the OGD model, P4 and VDH each showed neuroprotection individually, but combination of the “best” doses did not show substantial efficacy; instead, the lower dose of VDH in combination with P4 was the most effective. In the tMCAO model, P4 and VDH were given alone or in combination at different times post-occlusion for 7 days. In vivo data confirmed the in vitro findings and showed better infarct reduction at day 7 and functional outcomes (at 3, 5 and 7 days post-occlusion) after combinatorial treatment than when either agent was given alone. VDH, but not P4, upregulated heme oxygenase-1, suggesting a pathway for the neuroprotective effects of VDH differing from that of P4. The combination of P4 and VDH activated brain-derived neurotrophic factor and its specific receptor, tyrosine kinase receptor-B. Under specific conditions VDH potentiates P4’s neuroprotective efficacy and should be considered as a potential partner of P4 in a low-cost, safe and effective combinatorial treatment for stroke.

The Seed of <i>Zizyphus jujuba</i> var. <i>spinosa</i> Attenuates Alzheimer’s Disease-Associated Hippocampal Synaptic Deficits through BDNF/TrkB Signaling

“…34,35) Most neuroprotective actions of BDNF are mediated by TrkB receptor; therefore, mBDNF is considered the predominant form that exerts neuroprotective effects on various brain diseases. 36,37) A previous study indicated that extracellular conversion of proBDNF to mBDNF by the tissue plasminogen activator (tPA)/plasmin protease system is critical for late-phase LTP. 38) Moreover, tPA/plasmin system activation resulted in neuroprotection by increasing mBDNF.…”

Progesterone in transient ischemic stroke: a dose–response study

“…PROG effects are currently being studied under two independent phase III clinical trials for TBI (Protect III, at http://www.clinicaltrials.gov/NCT00822900; SyNAPSe, at http://www.synapse-trial.com). Increasing pre-clinical evidence from our and other laboratories around the world provides important corroboration that PROG treatment improves functional recovery and reduces brain infarction in different stroke models (Atif et al 2013; Yousuf et al 2013; De Nicola et al 2013; Gibson et al 2011; Wong et al 2013). …”

Estudo das células Neuro2A sobre os biomateriais PCL e PLLA

“…Como base nos resultados expressos acima, podemos observar que a técnica de solvente apresentado nesta metodologia evidencia a ausência de toxicidade celular nas membranas poliméricas, pelo fato das células apresentarem a integridade nuclear, observada pela coloração com o DAPI, bem como a presença da atividade nuclear, evidenciada pela intensa marcação com o PCNA. Não obstante, o pesquisador Atif et al [42] , utilizou o PCNA e DAPI em seu trabalho, o qual investigou a ação da progesterona na inibição do neuroblastoma. Ainda, Hossain et al [43] ao estudar uma nova terapia para o tratamento de neuroblastoma, através da expressão do oncogene N-myc utilizando ARN, agregado ao plasmídeo (shRNA) com a finalidade de aumentar a eficácia antitumoral da apigenina isoflavonoide (APG), avaliaram a morfologia celular e a apoptose nuclear através da marcação com DAPI.…”